JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Elanco Animal Health Inc

Geschlossen

BrancheGesundheitswesen

22.75 1.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.51

Max

22.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

-198M

-232M

Verkäufe

7M

1.1B

KGV

Branchendurchschnitt

372.714

60.328

Gewinnspanne

-20.28

Angestellte

9,400

EBITDA

-172M

6M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+31.31% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-472M

12B

Vorheriger Eröffnungskurs

21.23

Vorheriger Schlusskurs

22.75

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Elanco Animal Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Mai 2025, 11:29 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Non-Core Asset to Blackstone for $295 Million

5. Mai 2025, 11:14 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5. Mai 2025, 10:50 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5. Mai 2025, 10:49 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

Peer-Vergleich

Kursveränderung

Elanco Animal Health Inc Prognose

Kursziel

By TipRanks

31.31% Vorteil

12-Monats-Prognose

Durchschnitt 29.4 USD  31.31%

Hoch 32 USD

Tief 24 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Elanco Animal Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

10

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

9.77 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
help-icon Live chat